MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance

Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at incre...

Full description

Saved in:
Bibliographic Details
Published inHead & neck Vol. 33; no. 6; pp. 786 - 791
Main Authors Dai, Yuemeng, Xie, Cheng-hui, Neis, John P., Fan, Chun-Yang, Vural, Emre, Spring, Paul M.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2011
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5‐fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross‐resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross‐resistance. Resistant cells showed significant downregulation of miR‐100, miR‐130a, and miR‐197 and upregulation in miR‐101, miR‐181b, miR‐181d, and miR‐195 expression when compared with their parent cells (p < .01). Real‐time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR‐100 and miR‐130a and upregulation in miR‐181d expression (p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. © 2010 Wiley Periodicals, Inc. Head Neck, 2011
AbstractList Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. [copy 2010 Wiley Periodicals, Inc. Head Neck, 2011
BACKGROUNDThe purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer.METHODSHead and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells.RESULTSDocetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001).CONCLUSIONAlterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR.
Abstract Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5‐fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross‐resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross‐resistance. Resistant cells showed significant downregulation of miR‐100, miR‐130a, and miR‐197 and upregulation in miR‐101, miR‐181b, miR‐181d, and miR‐195 expression when compared with their parent cells ( p < .01). Real‐time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR‐100 and miR‐130a and upregulation in miR‐181d expression ( p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. © 2010 Wiley Periodicals, Inc. Head Neck, 2011
The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Docetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001). Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR.
Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5‐fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross‐resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross‐resistance. Resistant cells showed significant downregulation of miR‐100, miR‐130a, and miR‐197 and upregulation in miR‐101, miR‐181b, miR‐181d, and miR‐195 expression when compared with their parent cells (p < .01). Real‐time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR‐100 and miR‐130a and upregulation in miR‐181d expression (p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. © 2010 Wiley Periodicals, Inc. Head Neck, 2011
Author Dai, Yuemeng
Fan, Chun-Yang
Xie, Cheng-hui
Spring, Paul M.
Neis, John P.
Vural, Emre
Author_xml – sequence: 1
  givenname: Yuemeng
  surname: Dai
  fullname: Dai, Yuemeng
  organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas
– sequence: 2
  givenname: Cheng-hui
  surname: Xie
  fullname: Xie, Cheng-hui
  organization: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
– sequence: 3
  givenname: John P.
  surname: Neis
  fullname: Neis, John P.
  organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas
– sequence: 4
  givenname: Chun-Yang
  surname: Fan
  fullname: Fan, Chun-Yang
  organization: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
– sequence: 5
  givenname: Emre
  surname: Vural
  fullname: Vural, Emre
  email: VuralEmreA@uams.edu
  organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas
– sequence: 6
  givenname: Paul M.
  surname: Spring
  fullname: Spring, Paul M.
  organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24181023$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21560177$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv1DAUhS1URB-w4A8gbxBlkdaOHTtZltJOQaWIl0BsLMe-ZkwTZ8ZO1Om_x8PMwApWvrK--zjnHKK9MARA6CklJ5SQ8nQO9qSkFScP0AEljSwI43JvXXNWMCL5PjpM6SchhAlePkL7GRaESnmAlu-8icPHmzMMq0WElPwQ8CIOzneQ8ODwHLTFOlgcwNzitJx0P0wJG-g6bHQ0Pgy9xnd-nGM7GBj1CrrCBzsZsLifutHbOP3AebRPow4GHqOHTncJnmzfI_Tl8uLz-VVx_X725vzsujC8rEjRGEKEsw1AVVYArqWmMjTfz2StWya1a4Xg3Lq6ZC3TunZ0rUiIpqYNMzU7Qi82c7Oa5QRpVL1P67N1gKxA1ULkPYTSTB7_l6Rc1KxiFeUZfblBs2kpRXBqEX2v472iRK2zUDkL9TuLzD7bjp3aPv_uyJ35GXi-BXQyunMx2-PTX47TmpKSZe50w93lUO7_vVFdXbzerS42HdlzWP3p0PFWCclkpb7ezNTs1Tfy4VP9Xb1lvwCdGrFK
CitedBy_id crossref_primary_10_1016_j_molcel_2014_05_005
crossref_primary_10_3892_ol_2016_4892
crossref_primary_10_3892_or_2012_2155
crossref_primary_10_1016_j_mtadv_2023_100407
crossref_primary_10_3892_mmr_2017_6173
crossref_primary_10_1016_j_oraloncology_2020_105002
crossref_primary_10_1186_s13046_016_0296_0
crossref_primary_10_1093_abbs_gmt113
crossref_primary_10_1038_s41598_018_35799_1
crossref_primary_10_1038_s41392_020_00419_w
crossref_primary_10_1155_2015_186904
crossref_primary_10_1016_j_oraloncology_2020_104916
crossref_primary_10_18632_oncotarget_21235
crossref_primary_10_3390_ijms21072619
crossref_primary_10_1371_journal_pone_0117809
crossref_primary_10_1371_journal_pone_0051436
crossref_primary_10_1021_mp200255d
crossref_primary_10_1371_journal_pone_0107467
crossref_primary_10_1016_j_mrrev_2023_108467
crossref_primary_10_1016_j_gene_2016_06_035
crossref_primary_10_1111_jcmm_12131
crossref_primary_10_1016_j_jid_2021_01_028
crossref_primary_10_1007_s10238_022_00849_6
crossref_primary_10_1016_j_molonc_2013_12_011
crossref_primary_10_1177_0022034511431261
crossref_primary_10_1038_cddis_2013_548
crossref_primary_10_1038_mt_2015_10
crossref_primary_10_1002_pros_23031
crossref_primary_10_1007_s13277_014_2520_x
crossref_primary_10_1038_oncsis_2013_3
crossref_primary_10_1111_j_1600_0714_2011_01121_x
crossref_primary_10_1186_1746_1596_7_159
crossref_primary_10_1016_j_canep_2018_12_008
crossref_primary_10_3892_or_2013_2532
crossref_primary_10_1007_s10555_016_9625_1
crossref_primary_10_1177_1010428317698379
crossref_primary_10_1016_j_tjog_2014_06_007
crossref_primary_10_18632_oncotarget_1776
crossref_primary_10_5339_jlghs_2014_1
crossref_primary_10_1038_onc_2012_28
crossref_primary_10_1002_cac2_12138
crossref_primary_10_1016_j_addr_2015_05_001
crossref_primary_10_1016_j_ejca_2011_04_037
crossref_primary_10_1002_hed_26533
crossref_primary_10_1016_j_critrevonc_2013_07_012
crossref_primary_10_1007_s12094_015_1318_7
crossref_primary_10_3390_jpm12091436
crossref_primary_10_1016_j_molonc_2015_10_004
crossref_primary_10_1016_j_canlet_2011_11_024
crossref_primary_10_1124_pr_111_005637
crossref_primary_10_3892_mmr_2017_6233
crossref_primary_10_1016_j_ctrv_2012_07_005
crossref_primary_10_1016_j_prp_2023_154949
crossref_primary_10_1093_bib_bbs082
Cites_doi 10.1261/rna.2183803
10.2174/1381612043453117
10.2174/1568009054863609
10.1126/science.1064921
10.4161/cbt.5.5.2655
10.1016/S0304-3835(99)00263-3
10.1038/sj.onc.1210681
10.1159/000086183
10.1056/NEJMra001375
10.1016/j.ccr.2006.01.025
10.1038/sj.bjc.6600685
10.1016/j.bcp.2008.06.007
10.1074/jbc.270.52.31269
10.3322/canjclin.55.2.74
10.1002/cncr.11063
10.1146/annurev.biochem.71.102301.093055
10.1128/MCB.22.6.1844-1857.2002
10.1073/pnas.0509603102
10.1002/1097-0215(200102)9999:9999<::AID-IJC1180>3.0.CO;2-T
10.1002/ijc.23501
10.2174/1568011053765967
10.1007/BF00744663
10.1158/0008-5472.CAN-07-2488
10.1016/j.ctrv.2008.03.002
10.1016/0065-2571(94)90025-6
10.1038/nrc706
10.1093/oxfordjournals.annonc.a058903
10.1158/0008-5472.CAN-05-1783
ContentType Journal Article
Copyright Copyright © 2010 Wiley Periodicals, Inc.
2015 INIST-CNRS
Copyright_xml – notice: Copyright © 2010 Wiley Periodicals, Inc.
– notice: 2015 INIST-CNRS
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
7X8
DOI 10.1002/hed.21540
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList Nucleic Acids Abstracts
MEDLINE - Academic
CrossRef
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1097-0347
EndPage 791
ExternalDocumentID 10_1002_hed_21540
21560177
24181023
HED21540
ark_67375_WNG_GBX0QS8Z_J
Genre article
Research Support, U.S. Gov't, Non-P.H.S
Journal Article
GrantInformation_xml – fundername: Veterans Administration Advanced Research Career Development Award (PMS)
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DUUFO
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6P
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
AAUGY
AAVGM
ABHUG
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TM
7X8
ID FETCH-LOGICAL-c4250-9c006fd9ee525eefb1c5c1364378ab37afb6644df823b3aa8f101776698193c83
IEDL.DBID DR2
ISSN 1043-3074
1097-0347
IngestDate Sat Aug 17 01:54:34 EDT 2024
Sat Aug 17 01:12:58 EDT 2024
Fri Aug 23 05:02:57 EDT 2024
Sat Sep 28 08:34:04 EDT 2024
Sun Oct 22 16:05:00 EDT 2023
Sat Aug 24 00:57:00 EDT 2024
Wed Oct 30 09:52:40 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Antineoplastic agent
multidrug resistance
RNA
Stomatology
Docetaxel
ENT
Malignant tumor
Profile
Resistance
Taxane derivatives
Head and neck
ENT disease
Head and neck cancer
Head and neck squamous cell carcinoma
Antimitotic
micro-RNA
Cancer
Language English
License CC BY 4.0
Copyright © 2010 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4250-9c006fd9ee525eefb1c5c1364378ab37afb6644df823b3aa8f101776698193c83
Notes ArticleID:HED21540
istex:7ED381CA2930F15B0C591AA22FC4D26895261753
ark:/67375/WNG-GBX0QS8Z-J
Veterans Administration Advanced Research Career Development Award (PMS)
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 21560177
PQID 1468353514
PQPubID 23462
PageCount 6
ParticipantIDs proquest_miscellaneous_866250011
proquest_miscellaneous_1468353514
crossref_primary_10_1002_hed_21540
pubmed_primary_21560177
pascalfrancis_primary_24181023
wiley_primary_10_1002_hed_21540_HED21540
istex_primary_ark_67375_WNG_GBX0QS8Z_J
PublicationCentury 2000
PublicationDate June 2011
PublicationDateYYYYMMDD 2011-06-01
PublicationDate_xml – month: 06
  year: 2011
  text: June 2011
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle Head & neck
PublicationTitleAlternate Head Neck
PublicationYear 2011
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley
References El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002; 22: 1844-1857.
Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14 Suppl 1: 35-48.
Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 2004; 10: 647-657.
Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433.
Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 1995; 270: 31269-31275.
Mizumachi T, Suzuki S, Naito A, et al. Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 2008; 27: 831-838.
Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park) 1998; 12( 10 Suppl 7): 19-22.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
Dey S, Spring PM, Amold S, et al. Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 2003; 9: 1557-1565.
Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994; 34: 397-419.
Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2003; 88: 11-17.
Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
Moscow JA, Dixon KH. Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology 1993; 12: 155-170.
Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. Cancer Res 1976; 36: 2891-2895.
Zhu B, Liu GT, Zhao YM, Wu RS, Strada SJ. Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2. Cancer Biol Ther 2006; 5: 536-543.
Schöndorf T, Scharl A, Kurbacher CM, et al. Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett 1999; 146: 195-199.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
Meijerman I, Beijnen JH, Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 2008; 34: 505-520.
Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003; 97: 412-418.
Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251-265.
He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005; 102: 19075-19080.
Lagos-Quintana M, Rauhut R, Landeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858.
Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-588.
Uematsu T, Hasegawa T, Hiraoka BY, et al. Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 2001; 92: 187-194.
Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900.
Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495-505.
Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747-754.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537-592.
Mahadevan D, Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 2005; 5: 445-455.
Ambros V, Bartel B, Bartel DP, et al. A uniform system for microRNA annotation. RNA 2003; 9: 277-279.
2001; 92
2006; 9
2002; 2
2008; 34
2006; 5
2005; 65
1999; 146
2008; 76
2008; 123
2003; 97
2001; 345
1995; 270
2004; 10
1993; 12
2001; 294
1976; 36
2005; 102
1993; 53
2008; 27
2002; 22
2003; 9
1994; 34
2005; 5
2008; 68
2002; 71
2005; 55
1994; 5
1998; 12
2003; 88
2005; 14
e_1_2_6_31_2
e_1_2_6_30_2
e_1_2_6_18_2
Momparler RL (e_1_2_6_23_2) 1976; 36
e_1_2_6_19_2
Dey S (e_1_2_6_14_2) 2003; 9
e_1_2_6_12_2
e_1_2_6_13_2
e_1_2_6_10_2
e_1_2_6_33_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_16_2
e_1_2_6_17_2
e_1_2_6_15_2
e_1_2_6_20_2
Lokich J (e_1_2_6_24_2) 1998; 12
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_9_2
e_1_2_6_29_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
Gottesman MM (e_1_2_6_22_2) 1993; 53
e_1_2_6_2_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_27_2
e_1_2_6_26_2
e_1_2_6_25_2
References_xml – volume: 10
  start-page: 647
  year: 2004
  end-page: 657
  article-title: Cyclooxygenase‐2: potential role in regulation of drug efflux and multidrug resistance phenotype
  publication-title: Curr Pharm Des
– volume: 294
  start-page: 853
  year: 2001
  end-page: 858
  article-title: Identification of novel genes coding for small expressed RNAs
  publication-title: Science
– volume: 5
  start-page: 445
  year: 2005
  end-page: 455
  article-title: Strategies for targeting the multidrug resistance‐1 (MDR1)/P‐gp transporter in human malignancies
  publication-title: Curr Cancer Drug Targets
– volume: 9
  start-page: 277
  year: 2003
  end-page: 279
  article-title: A uniform system for microRNA annotation
  publication-title: RNA
– volume: 65
  start-page: 7065
  year: 2005
  end-page: 7070
  article-title: MicroRNA gene expression deregulation in human breast cancer
  publication-title: Cancer Res
– volume: 92
  start-page: 187
  year: 2001
  end-page: 194
  article-title: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous‐cell carcinomas
  publication-title: Int J Cancer
– volume: 27
  start-page: 831
  year: 2008
  end-page: 838
  article-title: Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells
  publication-title: Oncogene
– volume: 97
  start-page: 412
  year: 2003
  end-page: 418
  article-title: Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience
  publication-title: Cancer
– volume: 123
  start-page: 372
  year: 2008
  end-page: 379
  article-title: miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells
  publication-title: Int J Cancer
– volume: 9
  start-page: 189
  year: 2006
  end-page: 198
  article-title: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
  publication-title: Cancer Cell
– volume: 55
  start-page: 74
  year: 2005
  end-page: 108
  article-title: Global cancer statistics, 2002
  publication-title: CA Cancer J Clin
– volume: 12
  start-page: 155
  year: 1993
  end-page: 170
  article-title: Glutathione‐related enzymes, glutathione and multidrug resistance
  publication-title: Cytotechnology
– volume: 270
  start-page: 31269
  year: 1995
  end-page: 31275
  article-title: Altered expression of M beta 2, the class II beta‐tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance
  publication-title: J Biol Chem
– volume: 71
  start-page: 537
  year: 2002
  end-page: 592
  article-title: Mammalian ABC transporters in health and disease
  publication-title: Annu Rev Biochem
– volume: 68
  start-page: 425
  year: 2008
  end-page: 433
  article-title: MicroRNA expression profiling in human ovarian cancer: miR‐214 induces cell survival and cisplatin resistance by targeting PTEN
  publication-title: Cancer Res
– volume: 34
  start-page: 505
  year: 2008
  end-page: 520
  article-title: Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer
  publication-title: Cancer Treat Rev
– volume: 9
  start-page: 1557
  year: 2003
  end-page: 1565
  article-title: Low‐dose fractionated radiation potentiates the effects of paclitaxel in wild‐type and mutant p53 head and neck tumor cell lines
  publication-title: Clin Cancer Res
– volume: 53
  start-page: 747
  year: 1993
  end-page: 754
  article-title: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture
  publication-title: Cancer Res
– volume: 5
  start-page: 251
  year: 2005
  end-page: 265
  article-title: Cisplatin is a DNA‐damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways
  publication-title: Curr Med Chem Anticancer Agents
– volume: 88
  start-page: 11
  year: 2003
  end-page: 17
  article-title: Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
  publication-title: Br J Cancer
– volume: 36
  start-page: 2891
  year: 1976
  end-page: 2895
  article-title: Effect of adriamycin on DNA, RNA and protein synthesis in cell‐free systems and intact cells
  publication-title: Cancer Res
– volume: 76
  start-page: 582
  year: 2008
  end-page: 588
  article-title: Role of microRNA miR‐27a and miR‐451 in the regulation of MDR1/P‐glycoprotein expression in human cancer cells
  publication-title: Biochem Pharmacol
– volume: 34
  start-page: 397
  year: 1994
  end-page: 419
  article-title: The methotrexate story: a paradigm for development of cancer chemotherapeutic agents
  publication-title: Adv Enzyme Regul
– volume: 12
  start-page: 19
  issue: 10 Suppl 7
  year: 1998
  end-page: 22
  article-title: Infusional 5‐FU: historical evolution, rationale, and clinical experience
  publication-title: Oncology (Williston Park)
– volume: 5
  start-page: 495
  year: 1994
  end-page: 505
  article-title: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind
  publication-title: Ann Oncol
– volume: 14
  start-page: 35
  issue: Suppl 1
  year: 2005
  end-page: 48
  article-title: Mechanisms of drug resistance in cancer chemotherapy
  publication-title: Med Princ Pract
– volume: 345
  start-page: 1890
  year: 2001
  end-page: 1900
  article-title: Head and neck cancer
  publication-title: N Engl J Med
– volume: 5
  start-page: 536
  year: 2006
  end-page: 543
  article-title: Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p‐glycoprotein, GST‐P and Bcl‐2
  publication-title: Cancer Biol Ther
– volume: 102
  start-page: 19075
  year: 2005
  end-page: 19080
  article-title: The role of microRNA genes in papillary thyroid carcinoma
  publication-title: Proc Natl Acad Sci U S A
– volume: 2
  start-page: 48
  year: 2002
  end-page: 58
  article-title: Multidrug resistance in cancer: role of ATP‐dependent transporters
  publication-title: Nat Rev Cancer
– volume: 22
  start-page: 1844
  year: 2002
  end-page: 1857
  article-title: Precipitous release of methyl‐CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation
  publication-title: Mol Cell Biol
– volume: 146
  start-page: 195
  year: 1999
  end-page: 199
  article-title: Amplification of the mdr1‐gene is uncommon in recurrent ovarian carcinomas
  publication-title: Cancer Lett
– ident: e_1_2_6_17_2
  doi: 10.1261/rna.2183803
– ident: e_1_2_6_12_2
  doi: 10.2174/1381612043453117
– ident: e_1_2_6_30_2
  doi: 10.2174/1568009054863609
– ident: e_1_2_6_16_2
  doi: 10.1126/science.1064921
– volume: 12
  start-page: 19
  issue: 10
  year: 1998
  ident: e_1_2_6_24_2
  article-title: Infusional 5‐FU: historical evolution, rationale, and clinical experience
  publication-title: Oncology (Williston Park)
  contributor:
    fullname: Lokich J
– ident: e_1_2_6_13_2
  doi: 10.4161/cbt.5.5.2655
– ident: e_1_2_6_27_2
  doi: 10.1016/S0304-3835(99)00263-3
– volume: 36
  start-page: 2891
  year: 1976
  ident: e_1_2_6_23_2
  article-title: Effect of adriamycin on DNA, RNA and protein synthesis in cell‐free systems and intact cells
  publication-title: Cancer Res
  contributor:
    fullname: Momparler RL
– ident: e_1_2_6_29_2
  doi: 10.1038/sj.onc.1210681
– ident: e_1_2_6_11_2
  doi: 10.1159/000086183
– ident: e_1_2_6_3_2
  doi: 10.1056/NEJMra001375
– ident: e_1_2_6_18_2
  doi: 10.1016/j.ccr.2006.01.025
– ident: e_1_2_6_5_2
  doi: 10.1038/sj.bjc.6600685
– ident: e_1_2_6_32_2
  doi: 10.1016/j.bcp.2008.06.007
– ident: e_1_2_6_28_2
  doi: 10.1074/jbc.270.52.31269
– ident: e_1_2_6_2_2
  doi: 10.3322/canjclin.55.2.74
– volume: 9
  start-page: 1557
  year: 2003
  ident: e_1_2_6_14_2
  article-title: Low‐dose fractionated radiation potentiates the effects of paclitaxel in wild‐type and mutant p53 head and neck tumor cell lines
  publication-title: Clin Cancer Res
  contributor:
    fullname: Dey S
– ident: e_1_2_6_4_2
  doi: 10.1002/cncr.11063
– ident: e_1_2_6_7_2
  doi: 10.1146/annurev.biochem.71.102301.093055
– ident: e_1_2_6_10_2
  doi: 10.1128/MCB.22.6.1844-1857.2002
– ident: e_1_2_6_20_2
  doi: 10.1073/pnas.0509603102
– ident: e_1_2_6_15_2
  doi: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1180>3.0.CO;2-T
– ident: e_1_2_6_33_2
  doi: 10.1002/ijc.23501
– ident: e_1_2_6_26_2
  doi: 10.2174/1568011053765967
– volume: 53
  start-page: 747
  year: 1993
  ident: e_1_2_6_22_2
  article-title: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture
  publication-title: Cancer Res
  contributor:
    fullname: Gottesman MM
– ident: e_1_2_6_9_2
  doi: 10.1007/BF00744663
– ident: e_1_2_6_31_2
  doi: 10.1158/0008-5472.CAN-07-2488
– ident: e_1_2_6_6_2
  doi: 10.1016/j.ctrv.2008.03.002
– ident: e_1_2_6_25_2
  doi: 10.1016/0065-2571(94)90025-6
– ident: e_1_2_6_8_2
  doi: 10.1038/nrc706
– ident: e_1_2_6_21_2
  doi: 10.1093/oxfordjournals.annonc.a058903
– ident: e_1_2_6_19_2
  doi: 10.1158/0008-5472.CAN-05-1783
SSID ssj0003642
Score 2.3213964
Snippet Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance...
The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in...
Abstract Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug...
Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance...
BACKGROUNDThe purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 786
SubjectTerms 5-Fluorouracil
Antineoplastic Agents - pharmacology
Biological and medical sciences
cancer
Carcinoma - drug therapy
Carcinoma - genetics
Carcinoma, Squamous Cell
Cell Line, Tumor - drug effects
Docetaxel
Drug Resistance, Multiple - genetics
Drug Resistance, Neoplasm - genetics
Gene Expression Regulation, Neoplastic
head and neck
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - genetics
Humans
Medical sciences
micro-RNA
MicroRNAs - genetics
multidrug resistance
Neoplasms, Squamous Cell - drug therapy
Neoplasms, Squamous Cell - genetics
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Pharmacogenetics
Reverse Transcriptase Polymerase Chain Reaction
Sensitivity and Specificity
Squamous Cell Carcinoma of Head and Neck
Taxoids - pharmacology
Tumors
Title MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance
URI https://api.istex.fr/ark:/67375/WNG-GBX0QS8Z-J/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhed.21540
https://www.ncbi.nlm.nih.gov/pubmed/21560177
https://search.proquest.com/docview/1468353514
https://search.proquest.com/docview/866250011
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB5V7YULD_FyKdWCEOLi1Pba67V6KvQRVWokChURQrL2ZUChDsSJFPXUn8Bv5Jcws44TBVEJcfNhbWtnZ3a-nZ35BuBFFtlCqCwPk0LokPIuQlUJExYuToRF85M51TufDUT_Ij0dZsMN2O9qYVp-iGXAjSzD79dk4Eo3eyvS0C_O9tBfpXRej3lO6VyH5yvqKC7S9qYz5RRfSTtWoSjZW7655ou2SKxzyo1UDYqnavta_A14ruNY74iO78Cnbgpt_smoN5vqnrn6g93xP-d4F24vACo7aDXqHmy4-j40Z5S3dz44YG6-yJyt2aLdd8PGFcMt3TJVW1Y7M2LNj5mikAKjawFmqF1RPb5UjIK-zKLHnKq5-_br-ufX2qJqWebTGu1k9pnhxwnRoio-gIvjo_dv-uGiXUNo0PCjsDBowZUtnMuSzLlKxyYzMaebQak0z1WlBaIvW8mEa66UrGg7yIUoEJVwI_lD2KzHtXsMTNpYizz3ZIOpiwvtsshJ6XLFjY6MC-B5t3Dl95aVo2z5l5MSZVZ6mQXw0i_pcoSajCiNLc_KD4OT8uT1MHr7Tn4sTwPYXVvz5QuIbiRRWwTwrFOCEq2PZKdqh2KkgxNCWKqGCIDdMEYKPGMS9A7gUatAqx9QHTvKIIBXXg1unkzZPzr0D9v_PvQJ3Goj4BQz2oHN6WTmniKEmupdbyu_ASHxF5A
link.rule.ids 315,783,787,1378,27938,27939,46308,46732
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB5V7QEuPMTLPMqCEOLi1Pba67XEpdBHKE0kSiuiSmi1LwMKOJCHFHHiJ_Ab-SXM2HGiICohbj6sbe3szM63szPfADzJIlcIneVhUggTUt5FqEthw8LHiXBofjKneudeX3TP0qNBNtiA520tTMMPsQy4kWXU-zUZOAWkd1asoR-966DDSvHAvoXmzql_wd7JijyKi7S560w5RVjSllcoSnaWr655oy0S7JyyI_UEBVQ2nS3-Bj3XkWztig6uwvt2Ek0GyrAzm5qO_f4Hv-P_zvIaXFlgVLbbKNV12PDVDZj0KHXvpL_L_HyRPFuxRcfvCRuVDHd1x3TlWOXtkE2-zTRFFRjdDDBLHYuq0RfNKO7LHDrNqZ77z79-_PxUOdQux-rMRjeefWD4cQK1qI034exg__RlN1x0bAgt2n4UFhaNuHSF91mSeV-a2GY25nQ5KLXhuS6NQADmSplww7WWJe0IuRAFAhNuJb8Fm9Wo8neASRcbkec132Dq48L4LPJS-lxzayLrA3jcrpz62hBzqIaCOVEoM1XLLICn9ZouR-jxkDLZ8ky96x-qwxeD6M1bea6OAtheW_TlCwhwJLFbBPCo1QKFBkiy05VHMdLZCVEsFUQEwC4YIwUeMwl9B3C70aDVD6iUHWUQwLNaDy6ejOru79UPd_996EO41D3tHavjV_3X9-ByExCnENJ92JyOZ_4BIqqp2a4N5zd7WBuq
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VrYS48BCvUCgGIcQl2yROHEecCtvtUugKChWrCsnyKxQtZMs-pBUnfgK_kV_CTLIPLaIS4paDk8jjGc_n8cw3AI-zyBVCZ3mYFMKElHcR6lLYsPBxIhyan8yp3vmoJ7on6WE_62_As0UtTMMPsQy4kWXU-zUZ-Lkrd1ekoWfetdBfpXhe30oFjyifq3284o7iIm2uOlNOAZZ0QSsUJbvLV9ec0RbJdUbJkXqM8imbxhZ_Q57rQLb2RJ2r8HExhyYBZdCaTkzLfv-D3vE_J3kNrswRKttrVOo6bPjqBoyPKHHvuLfH_GyeOluxeb_vMRuWDPd0x3TlWOXtgI2_TTXFFBjdCzBL_Yqq4VfNKOrLHLrMiZ75L79-_PxcOdQtx-q8RjeafmL4cYK0qIs34aSz__5FN5z3awgtWn4UFhZNuHSF91mSeV-a2GY25nQ1KLXhuS6NQPjlSplww7WWJe0HuRAFwhJuJb8Fm9Ww8neASRcbkec122Dq48L4LPJS-lxzayLrA3i0WDh13tByqIaAOVEoM1XLLIAn9ZIuR-jRgPLY8kx96B2og-f96O07eaoOA9hZW_PlCwhvJHFbBPBwoQQKzY9kpyuPYqSTE2JYKocIgF0wRgo8ZBL2DuB2o0CrH1AhO8oggKe1Glw8GdXdb9cPd_996AO49KbdUa9f9l5tw-UmGk7xo3uwORlN_X2EUxOzU5vNbxwJGlk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA+expression+profiles+of+head+and+neck+squamous+cell+carcinoma+with+docetaxel-induced+multidrug+resistance&rft.jtitle=Head+%26+neck&rft.au=Dai%2C+Yuemeng&rft.au=Xie%2C+Cheng-hui&rft.au=Neisiv%2C+John+P&rft.au=Fan%2C+Chun-Yang&rft.date=2011-06-01&rft.issn=1097-0347&rft.volume=33&rft.issue=6&rft.spage=786&rft.epage=791&rft_id=info:doi/10.1002%2Fhed.21540&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-3074&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-3074&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-3074&client=summon